Annual Drug Patent Expirations for CAPLYTA
Caplyta is a drug marketed by Intra-cellular and is included in one NDA. There are ten patents protecting this drug.
Drug patent litigation for CAPLYTA.
This drug has one hundred and thirty-nine patent family members in twenty-six countries.
The generic ingredient in CAPLYTA is lumateperone tosylate. Additional details are available on the lumateperone tosylate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
